Elia Stupka

Elia Stupka

Auto-generated profile, based on publicly available information

Elia Stupka

Center for Translational Genomics and Bioinformatics, San Raffaele Scientific Institute, Milan, Italy

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2001 in Nature
Verified
Journal Article
Open access
PDF file
ELEric S. Lander
Eric S. Lander
LLLauren M. Linton
Lauren M. Linton
BBBruce Birren
Bruce Birren
CNChad Nusbaum
Chad Nusbaum
MZMichael C. Zody
Michael C. Zody
MMMichael J. Morgan
Michael J. Morgan
The human genome holds an extraordinary trove of information about human development, physiology, medicine and evolution. Here we report the results of an international collaboration to produce and make freely available a draft sequence of the human genome. We also present an initial analysis of the data, describing some of the insights that can be gleaned from the sequence.

2 September 2005 in Science
Verified
Journal Article
Closed access
PDF file
Piero CarninciPiero Carninci
Piero Carninci
TKT. Kasukawa
T. Kasukawa
SKS. Katayama
S. Katayama
JGJ. Gough
J. Gough
MFM. C. Frith
M. C. Frith
YHY. Hayashizaki
Y. Hayashizaki
This study describes comprehensive polling of transcription start and termination sites and analysis of previously unidentified full-length complementary DNAs derived from the mouse genome. We identify the 5′ and 3′ boundaries of 181,047 transcripts with extensive variation in transcripts arising from alternative promoter usage, splicing, and polyadenylation. There are 16,247 new mouse protein-coding transcripts, including 5154 encoding previously unidentified proteins. Genomic mapping of the transcriptome reveals transcriptional forests, with overlapping transcription on both strands, separated by deserts in which few transcripts are observed. The data provide a comprehensive platform for the comparative analysis of mammalian transcriptional regulation in differentiation and development.

1 October 2002 in Genome Research
Verified
Journal Article
Open access
PDF file
JSJason Stajich
Jason Stajich
DBDavid Block
David Block
KBKris Boulez
Kris Boulez
SBSteven E. Brenner
Steven E. Brenner
SCStephen A. Chervitz
Stephen A. Chervitz
EBEwan Birney
Ewan Birney
The Bioperl project is an international open-source collaboration of biologists, bioinformaticians, and computer scientists that has evolved over the past 7 yr into the most comprehensive library of Perl modules available for managing and manipulating life-science information. Bioperl provides an easy-to-use, stable, and consistent programming interface for bioinformatics application programmers. The Bioperl modules have been successfully and repeatedly used to reduce otherwise complex tasks to only a few lines of code. The Bioperl object model has been proven to be flexible enough to support enterprise-level applications such as EnsEMBL, while maintaining an easy learning curve for novice Perl programmers. Bioperl is capable of executing analyses and processing results from programs such as BLAST, ClustalW, or the EMBOSS suite. Interoperation with modules written in Python and Java is supported through the evolving BioCORBA bridge. Bioperl provides access to data stores such as GenBank and SwissProt via a flexible series of sequence input/output modules, and to the emerging common sequence data storage format of the Open Bioinformatics Database Access project. This study describes the overall architecture of the toolkit, the problem domains that it addresses, and gives specific examples of how the toolkit can be used to solve common life-sciences problems. We conclude with a discussion of how the open-source nature of the project has contributed to the development effort.[Supplemental material is available online at www.genome.org. Bioperl is available as open-source software free of charge and is licensed under the Perl Artistic License (http://www.perl.com/pub/a/language/misc/Artistic.html). It is available for download at http://www.bioperl.org. Support inquiries should be addressed to bioperl-l@bioperl.org.]

23 August 2002 in Science
Verified
Journal Article
Closed access
PDF file
SASamuel Aparicio
Samuel Aparicio
JCJarrod Chapman
Jarrod Chapman
ESElia Stupka
Elia Stupka
NPNik Putnam
Nik Putnam
JCJer-Ming Chia
Jer-Ming Chia
SBSydney Brenner
Sydney Brenner
The compact genome of Fugu rubripes has been sequenced to over 95% coverage, and more than 80% of the assembly is in multigene-sized scaffolds. In this 365-megabase vertebrate genome, repetitive DNA accounts for less than one-sixth of the sequence, and gene loci occupy about one-third of the genome. As with the human genome, gene loci are not evenly distributed, but are clustered into sparse and dense regions. Some “giant” genes were observed that had average coding sequence sizes but were spread over genomic lengths significantly larger than those of their human orthologs. Although three-quarters of predicted human proteins have a strong match to Fugu , approximately a quarter of the human proteins had highly diverged from or had no pufferfish homologs, highlighting the extent of protein evolution in the 450 million years since teleosts and mammals diverged. Conserved linkages between Fugu and human genes indicate the preservation of chromosomal segments from the common vertebrate ancestor, but with considerable scrambling of gene order.

23 August 2013 in Science
Verified
Journal Article
Closed access
PDF file
ABAlessandra Biffi
Alessandra Biffi
EMEugenio Montini
Eugenio Montini
LLLaura Lorioli
Laura Lorioli
MCMartina Cesani
Martina Cesani
FFFrancesca Fumagalli
Francesca Fumagalli
LNLuigi Naldini
Luigi Naldini
Next-Generation Gene Therapy: Few disciplines in contemporary clinical research have experienced the high expectations directed at the gene therapy field. However, gene therapy has been challenging to translate to the clinic, often because the therapeutic gene is expressed at insufficient levels in the patient or because the gene delivery vector integrates near protooncogenes, which can cause leukemia (see the Perspective by Verma ). Biffi et al. ( 1233158 , published online 11 July) and Aiuti et al. ( 1233151 ; published online 11 July) report progress on both fronts in gene therapy trials of three patients with metachromatic leukodystrophy (MLD), a neurodegenerative disorder, and three patients with Wiskott-Aldrich syndrome (WAS), an immunodeficiency disorder. Optimized lentiviral vectors were used to introduce functional MLD or WAS genes into the patients' hematopoietic stem cells (HSCs) ex vivo, and the transduced cells were then infused back into the patients, who were then monitored for up to 2 years. In both trials, the patients showed stable engraftment of the transduced HSC and high expression levels of functional MLD or WAS genes. Encouragingly, there was no evidence of lentiviral vector integration near proto-oncogenes, and the gene therapy treatment halted disease progression in most patients. A longer follow-up period will be needed to further validate efficacy and safety.

14 October 2012 in Nature
Verified
Journal Article
Closed access
CCClaudia Carrieri
Claudia Carrieri
LCLaura Cimatti
Laura Cimatti
MBMarta Biagioli
Marta Biagioli
ABAnne Beugnet
Anne Beugnet
SZSilvia Zucchelli
Silvia Zucchelli
SGStefano Gustincich
Stefano Gustincich